Vertex reports an earnings miss and pause on cystic fibrosis trial

Rising Costs Weigh on Vertex Q1 Earnings @themotleyfool #stocks $VRTX

Vertex misses on both lines in Q1 as 2025 revenue forecast narrowed

Vertex Pharmaceuticals Q1 results missed estimates, but the company raised its 2025 revenue outlook.

Vertex reports an earnings miss and pause on cystic fibrosis trial

Vertex shares fell in after-hours trading, as investors considered a stock trading near its high with a wait for its next leg of growth.

Vertex pauses study of mRNA therapy for cystic fibrosis

Vertex paused an early-stage trial of its inhaled treatment for cystic fibrosis that came from a partnership with Moderna. The biotech said Monday in its first-quarter press release that it's temporarily ...

#Vertex Pharmaceuticals Faces Mixed Quarter Strategic Expansion Amidst Earnings Challenges

In the recent financial landscape, Vertex Pharmaceuticals Inc. has reported its first-quarter results for 2025, which showcased a combination of resilience and challenges. Although shares have demonstrated an overall outperformance compared to the broader market year-to-date, the latest results have stirred investor apprehension. Despite the company's stocks experiencing a downturn of 5.96% during the current month, they have managed to outperfo…

Vertex Study: Global Tax and Finance Leaders Significantly Shift in Support of e-Invoicing

Vertex Study: Global Tax and Finance Leaders Significantly Shift in Support of e-Invoicing rbourne Tue, 05/06/2025 - 08:00 PDF VersionKing of Prussia, PA — May 6, 2025  -  Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced new e-invoicing research revealing that a majority (79%) of global business leaders believe e-invoicing mandates are beneficial to business. Furthermore…